Jerry Xiao, Ashton A Connor, Ahmed Elaileh, Khush Patel, Samar Semaan, Youssef Dib, Jason Todd, Linda W Moore, Sudha Kodali, David W Victor Iii, Maen Abdelrahim, Anaum Maqsood, Caroline J Simon, Yee Lee Cheah, Constance M Mobley, Ashish Saharia, A Osama Gaber, R Mark Ghobrial, Kirk Heyne
{"title":"Liver transplantation in patients with history of extra-hepatic malignancies.","authors":"Jerry Xiao, Ashton A Connor, Ahmed Elaileh, Khush Patel, Samar Semaan, Youssef Dib, Jason Todd, Linda W Moore, Sudha Kodali, David W Victor Iii, Maen Abdelrahim, Anaum Maqsood, Caroline J Simon, Yee Lee Cheah, Constance M Mobley, Ashish Saharia, A Osama Gaber, R Mark Ghobrial, Kirk Heyne","doi":"10.3389/frtra.2026.1723729","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Increasing use of solid organ transplantation [SOT] has coincided with increasing cancer survivorship. Consensus statements exist for SOT in patients with pre-transplant malignancy [PTM]. Yet, most outcomes have been reported in heart and kidney transplant. This paper addresses the shortage of information on liver transplant [LT] in patients with PTM.</p><p><strong>Methods: </strong>A retrospective case-control study was conducted of patients who underwent LT between 1/1/2008-5/31/2024 at an American transplant center. Patients were stratified according to history of extrahepatic PTM, time from PTM to LT, and post-LT PTM recurrence. Primary outcomes were overall survival [OS] and time to recurrence.</p><p><strong>Results: </strong>1,876 patients underwent LT. 143(7.62%) had an extrahepatic PTM pre-LT. PTM patients were older and had lower MELD at LT. There was no significant difference in post-LT survival (<i>p</i> = 0.293) between patients who did and did not have PTM. Of 121 patients with known time from PTM to LT, 19(15.7%) had an interval less than 2 years. When stratifying by 2-year interval from PTM to LT, there was no difference in survival (<i>p</i> = 0.34). Post-LT, 20 patients (14.0%) had recurrence of their PTM. The average time to recurrence was 595.5 days. When treated as a time-dependent co-variate, recurrence was a strong predictor of worse post-LT survival (HR 10.9, 95% CI 4.32-27.7, <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>In our experience<b>,</b> a history of pre-LT PTM, including with an interval to LT of less than 2 years, was not associated with worse post-LT survival. Recurrence of PTM did portend worse prognosis.</p>","PeriodicalId":519976,"journal":{"name":"Frontiers in transplantation","volume":"5 ","pages":"1723729"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in transplantation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/frtra.2026.1723729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Increasing use of solid organ transplantation [SOT] has coincided with increasing cancer survivorship. Consensus statements exist for SOT in patients with pre-transplant malignancy [PTM]. Yet, most outcomes have been reported in heart and kidney transplant. This paper addresses the shortage of information on liver transplant [LT] in patients with PTM.
Methods: A retrospective case-control study was conducted of patients who underwent LT between 1/1/2008-5/31/2024 at an American transplant center. Patients were stratified according to history of extrahepatic PTM, time from PTM to LT, and post-LT PTM recurrence. Primary outcomes were overall survival [OS] and time to recurrence.
Results: 1,876 patients underwent LT. 143(7.62%) had an extrahepatic PTM pre-LT. PTM patients were older and had lower MELD at LT. There was no significant difference in post-LT survival (p = 0.293) between patients who did and did not have PTM. Of 121 patients with known time from PTM to LT, 19(15.7%) had an interval less than 2 years. When stratifying by 2-year interval from PTM to LT, there was no difference in survival (p = 0.34). Post-LT, 20 patients (14.0%) had recurrence of their PTM. The average time to recurrence was 595.5 days. When treated as a time-dependent co-variate, recurrence was a strong predictor of worse post-LT survival (HR 10.9, 95% CI 4.32-27.7, p < 0.001).
Conclusion: In our experience, a history of pre-LT PTM, including with an interval to LT of less than 2 years, was not associated with worse post-LT survival. Recurrence of PTM did portend worse prognosis.